GleamWall
中文EN

BDTX Black Diamond Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1701541 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-305.0%
TTM EPS YoY-305.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.1%
ROA-32.3%
ROIC (approx.)-49.8%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio6.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$70.00M$0
R&D expense$33.56M$51.31M
SG&A expense$16.57M$27.47M
Operating income$12.52M-$78.78M
Pretax income$22.36M-$69.68M
Income tax$0$0
Net income$22.37M-$69.68M
EBITDA$12.85M-$78.44M
EPS (basic)0.39-1.27
EPS (diluted)0.39-1.27
Weighted avg. shares (diluted)57.56M55.03M
Balance sheet
Cash & equivalents$20.99M$37.26M
Short-term investments$107.66M$62.14M
Current assets$132.44M$101.18M
PP&E, net$365,000$1.39M
Total assets$143.01M$122.64M
Current liabilities$15.73M$20.57M
Total liabilities$30.80M$39.35M
Shareholders' equity$112.21M$83.28M
Shares outstanding57.14M56.64M
Cash flow statement
Operating cash flow$29.61M-$62.30M
Capital expenditure—$0
Free cash flow—-$62.30M
Investing cash flow-$44.91M$16.97M
Financing cash flow-$146,000$25.55M
Depreciation & amortization$325,000$343,000
Stock-based compensation$6.63M$10.63M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.